138 related articles for article (PubMed ID: 25048360)
21. Complex dendrimer-lyotropic liquid crystalline systems: structural behavior and interactions.
Bitan-Cherbakovsky L; Libster D; Aserin A; Garti N
J Phys Chem B; 2011 Oct; 115(42):11984-92. PubMed ID: 21902258
[TBL] [Abstract][Full Text] [Related]
22. The influence of mannose-based esters on the mesophase behaviour of lyotropic liquid crystalline nanosystems as drug delivery vectors.
Tiboni M; Astolfi P; Verboni M; Benedetti S; Giorgini E; Notarstefano V; Vita F; Ranieri S; Duranti A; Lucarini S; Casettari L; Pisani M
Colloids Surf B Biointerfaces; 2023 Dec; 232():113596. PubMed ID: 37918304
[TBL] [Abstract][Full Text] [Related]
23. The Effect of Prescription on the Framework of Lipid Matrix and In Vitro Properties.
Chu XQ; Zhang Y; Huang J; Li Q; Li ZG; Jiang JQ; Gui SY
Curr Drug Deliv; 2019; 16(8):737-750. PubMed ID: 31250753
[TBL] [Abstract][Full Text] [Related]
24. Formulation and characterization of a liquid crystalline hexagonal mesophase region of phosphatidylcholine, sorbitan monooleate, and tocopherol acetate for sustained delivery of leuprolide acetate.
Báez-Santos YM; Otte A; Mun EA; Soh BK; Song CG; Lee YN; Park K
Int J Pharm; 2016 Nov; 514(1):314-321. PubMed ID: 27863678
[TBL] [Abstract][Full Text] [Related]
25. Phospholipids-embedded fully dilutable liquid nanostructures. Part 2: The role of sodium diclofenac.
Amsalem O; Aserin A; Garti N
Colloids Surf B Biointerfaces; 2010 Dec; 81(2):422-9. PubMed ID: 20708909
[TBL] [Abstract][Full Text] [Related]
26. Solubilization of hydrophobic guest molecules in the monoolein discontinuous QL cubic mesophase and its soft nanoparticles.
Efrat R; Kesselman E; Aserin A; Garti N; Danino D
Langmuir; 2009 Feb; 25(3):1316-26. PubMed ID: 18781793
[TBL] [Abstract][Full Text] [Related]
27. Concentration- and temperature-induced effects of incorporated desmopressin on the properties of reverse hexagonal mesophase.
Libster D; Aserin A; Yariv D; Shoham G; Garti N
J Phys Chem B; 2009 May; 113(18):6336-46. PubMed ID: 19358543
[TBL] [Abstract][Full Text] [Related]
28. Molecular interactions in reverse hexagonal mesophase in the presence of Cyclosporin A.
Libster D; Ishai PB; Aserin A; Shoham G; Garti N
Int J Pharm; 2009 Feb; 367(1-2):115-26. PubMed ID: 18977286
[TBL] [Abstract][Full Text] [Related]
29. Spray dried glyceryl monooleate-magnesium trisilicate dry powder as cubic phase precursor.
Shah MH; Biradar SV; Paradkar AR
Int J Pharm; 2006 Oct; 323(1-2):18-26. PubMed ID: 16846704
[TBL] [Abstract][Full Text] [Related]
30. Improved solubilization of Celecoxib in U-type nonionic microemulsions and their structural transitions with progressive aqueous dilution.
Garti N; Avrahami M; Aserin A
J Colloid Interface Sci; 2006 Jul; 299(1):352-65. PubMed ID: 16529763
[TBL] [Abstract][Full Text] [Related]
31. Liquid crystalline Pluronic 105 pharmacogels as drug delivery systems: preparation, characterization, and in vitro transdermal release.
Muzzalupo R; Tavano L; Nicoletta FP; Trombino S; Cassano R; Picci N
J Drug Target; 2010 Jun; 18(5):404-11. PubMed ID: 20021229
[TBL] [Abstract][Full Text] [Related]
32. Lysozyme entrapped within reverse hexagonal mesophases: physical properties and structural behavior.
Mishraki T; Libster D; Aserin A; Garti N
Colloids Surf B Biointerfaces; 2010 Jan; 75(1):47-56. PubMed ID: 19748240
[TBL] [Abstract][Full Text] [Related]
33. Temperature-dependent behavior of lysozyme within the reverse hexagonal mesophases (H(II)).
Mishraki T; Libster D; Aserin A; Garti N
Colloids Surf B Biointerfaces; 2010 Feb; 75(2):391-7. PubMed ID: 19836212
[TBL] [Abstract][Full Text] [Related]
34. The role of glycerol and phosphatidylcholine in solubilizing and enhancing insulin stability in reverse hexagonal mesophases.
Amar-Yuli I; Azulay D; Mishraki T; Aserin A; Garti N
J Colloid Interface Sci; 2011 Dec; 364(2):379-87. PubMed ID: 21958442
[TBL] [Abstract][Full Text] [Related]
35. Interactions of biomacromolecules with reverse hexagonal liquid crystals: drug delivery and crystallization applications.
Libster D; Aserin A; Garti N
J Colloid Interface Sci; 2011 Apr; 356(2):375-86. PubMed ID: 21315366
[TBL] [Abstract][Full Text] [Related]
36. Cubic lyotropic liquid crystals as drug delivery carriers: Physicochemical and morphological studies.
Chountoulesi M; Pippa N; Pispas S; Chrysina ED; Forys A; Trzebicka B; Demetzos C
Int J Pharm; 2018 Oct; 550(1-2):57-70. PubMed ID: 30121331
[TBL] [Abstract][Full Text] [Related]
37. Formulation and
Madan JR; Ansari IN; Dua K; Awasthi R
Adv Pharm Bull; 2020 Jul; 10(3):408-417. PubMed ID: 32665899
[No Abstract] [Full Text] [Related]
38. Investigation of diclofenac release and dynamic structural behavior of non-lamellar liquid crystal formulations during in situ formation by UV-Vis imaging and SAXS.
Mertz N; Bock F; Østergaard J; Yaghmur A; Weng Larsen S
Int J Pharm; 2022 Jul; 623():121880. PubMed ID: 35661744
[TBL] [Abstract][Full Text] [Related]
39. Peptides modeled on the transmembrane region of the slow voltage-gated IsK potassium channel: structural characterization of peptide assemblies in the beta-strand conformation.
Aggeli A; Boden N; Cheng YL; Findlay JB; Knowles PF; Kovatchev P; Turnbull PJ
Biochemistry; 1996 Dec; 35(50):16213-21. PubMed ID: 8973194
[TBL] [Abstract][Full Text] [Related]
40. On the thermotropic and magnetotropic phase behavior of lipid liquid crystals containing magnetic nanoparticles.
Mendozza M; Montis C; Caselli L; Wolf M; Baglioni P; Berti D
Nanoscale; 2018 Feb; 10(7):3480-3488. PubMed ID: 29404545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
